Tonix Pharmaceuticals Holding Corp. - Common Stock (TNXP)
37.74
-2.33 (-5.81%)
NASDAQ · Last Trade: Aug 19th, 10:44 AM EDT
Detailed Quote
Previous Close
40.07
Open
36.90
Bid
37.50
Ask
37.80
Day's Range
34.00 - 38.83
52 Week Range
6.760 - 130.00
Volume
1,860,911
Market Cap
330.82M
PE Ratio (TTM)
-0.2110
EPS (TTM)
-178.9
Dividend & Yield
N/A (N/A)
1 Month Average Volume
2,138,512
Chart
About Tonix Pharmaceuticals Holding Corp. - Common Stock (TNXP)
Tonix Pharmaceuticals Holdings is a clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system disorders and other serious medical conditions. The company is dedicated to advancing its pipeline of product candidates, which include treatments for conditions such as migraines, post-traumatic stress disorder, and various infectious diseases. By leveraging its expertise in drug development and utilizing strategic collaborations, Tonix aims to bring novel treatment options to market that address unmet medical needs and improve patient outcomes. Read More
Intrigued by the market activity one hour before the close of the markets on Monday? Uncover the key winners and losers of today's session in our insightful analysis.
Curious to know what's happening on the US markets in the middle of the day on Monday? Join us as we explore the top gainers and losers in today's session.
As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Shares of Tonix Pharmaceuticals are trading sharply higher Tuesday morning. The stock is gaining following the release of the company's Q2 financial results and operational update.
NetworkNewsWire Editorial Coverage : As the American population gets older, chronic and rare diseases are becoming a significant healthcare issue, particularly for older adults. The aging population’s increasing life expectancy also leads to more complex healthcare needs, especially for conditions that are both chronic and difficult to diagnose. Many of these rare conditions lack FDA-approved treatments, and their symptoms in seniors are frequently mistaken for normal signs of aging, causing diagnostic delays that can last for years. There are more than 30 million Americans who have a rare disease, so there is a growing need for accurate diagnoses and effective treatments. The Trump administration’s “Make America Healthy Again” initiatives have highlighted this problem and focused on improving access to treatments and speeding up medical innovation. Soligenix Inc. (NASDAQ: SNGX) ( Profile ) is working to advance this mission with its HyBryte(“TM”) platform, a new therapy for cutaneous T-cell lymphoma (“CTCL”), a rare form of skin cancer that largely impacts older adults. The company has successfully established U.S.-based manufacturing for HyBryte’s active ingredient, demonstrating the kind of domestic innovation that can significantly help this underserved patient group. Soligenix is one of several notable companies dedicated to making an impact in the pharmaceutical field, alongside Amgen Inc. (NASDAQ: AMGN), Amicus Therapeutics Inc. (NASDAQ: FOLD), Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) and…
Tonix Pharmaceuticals (NASDAQ: TNXP), a fully integrated biopharmaceutical company, announced that Dr. Sina Bavari, Executive Vice President of Infectious Disease Research and Development, will present new preclinical data on TNX-801 at the Vaccine Congress 2025 in Vienna on July 10. TNX-801, a recombinant horsepox virus live vaccine candidate, has shown protective efficacy against mpox and other orthopoxviruses in animal models after a single dose. The platform is designed to induce durable immune responses and could be expanded to target other emerging viral threats. Dr. Bavari will highlight safety, immunogenicity, and efficacy findings, along with plans to initiate clinical trials.
Tonix Pharmaceuticals (NASDAQ: TNXP), a biopharmaceutical company advancing immunotherapy resistance solutions, announced the publication of new preclinical findings in Cancer Cell showing its fusion protein candidate mTNX-1700 increased survival and reduced metastases in mouse models of gastric cancer. Developed in collaboration with Columbia University Medical School, mTNX-1700—comprising murine trefoil factor-2 (mTFF2) and murine serum albumin—enhanced anti-PD-1 immunotherapy by depleting immunosuppressive neutrophils and curbing cancer-driven granulopoiesis. The human version, TNX-1700, is in development for gastric and colorectal cancers. CEO Dr. Seth Lederman said the findings support further development of TNX-1700 to overcome checkpoint resistance in solid tumors.
Tonix Pharmaceuticals (NASDAQ: TNXP), a fully integrated biotech company, announced its inclusion in the Russell 3000® and Russell 2000® Indexes following the 2025 Russell indexes reconstitution effective June 30. The addition reflects Tonix’s market cap growth and comes as the company prepares for potential FDA approval and launch of TNX-102 SL for fibromyalgia. CEO Seth Lederman noted the milestone will boost visibility as Tonix progresses toward commercialization. Russell indexes are widely used benchmarks, with $10.6 trillion in assets tied to their performance.
Tonix Pharmaceuticals (NASDAQ: TNXP) presented new data at the 2025 Annual European Congress of Rheumatology (EULAR) in Barcelona supporting TNX-102 SL, its sublingual cyclobenzaprine formulation for fibromyalgia. The poster highlighted results from the RESILIENT Phase 3 trial showing statistically significant, sustained pain reduction over 14 weeks, along with improved sleep and favorable tolerability. Designed to bypass first-pass liver metabolism, TNX-102 SL achieved higher nighttime cyclobenzaprine levels and lower norcyclobenzaprine accumulation compared to oral formulations, potentially enhancing long-term efficacy. With a Prescription Drug User Fee Act (PDUFA) goal date of Aug. 15, 2025, TNX-102 SL could become the first new fibromyalgia therapy in 15 years.
